Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT06113328) tested an investigational medicine called MK-6194 in people with vitiligo — a skin condition where patches of skin lose their colour. A total of 169 participants took part in the initial double-blind phase, split into three groups: 57 received MK-6194 by injection every two weeks (Q2W), 55 received it every four weeks (Q4W), and 57 received a placebo (a dummy treatment with no active ingredient). Those who completed that phase could continue into an extension period. The trial was primarily measuring changes in the extent of skin colour loss on the face and across the whole body, as well as tracking any unwanted medical events (called adverse events) that occurred during the study. The reported data shows that after 24 weeks, the facial skin colour loss score (called F-VASI — a scale where a lower score means less affected skin) changed by an average of −4.55% in the every-two-weeks MK-6194 group, −12.13% in the every-four-weeks group, and −4.01% in the placebo group. For the whole-body score (T-VASI), the reported changes were −1.69%, −9.08%, and +0.78% respectively — meaning the placebo group's score nudged slightly upward (suggesting a small increase in skin involvement on average). Regarding unwanted medical events, the reported data shows that 51 out of 57 participants in the every-two-weeks group, 47 out of 55 in the every-four-weeks group, and 44 out of 57 in the placebo group experienced at least one adverse event. The number of participants who stopped treatment because of an adverse event was 9, 5, and 1 in those same groups respectively. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Vitiligo Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with non-segmental vitiligo (the most common type, where patches appear on both sides of the body)
- You have had non-segmental vitiligo for at least 6 months
- The loss of skin color on your face meets a minimum level of severity based on a standard scoring tool called F-VASI (score of 0.3 or higher)
- At least 0.3% of the skin surface on your face has lost its color
- The overall loss of skin color across your body meets a minimum level of severity based on a standard scoring tool called T-VASI (score of 4 or higher)
- At least 4% of your total body skin has lost its color, not counting the hands and feet
Who may not be able to join:
- You have segmental vitiligo (the type that appears only on one side or part of the body)
- More than half of the hairs on your face or body have turned white or lost their color
- You have another skin condition that would make it hard to assess your vitiligo
- You have a current or past inflammatory condition (other than vitiligo) that could affect how the study evaluates your skin (confirm with trial site)
- You have a known allergy or serious reaction to the study drug or similar medicines
- You have had an active or significant infection recently — needing hospital treatment or IV antibiotics in the past 4 weeks, or oral/injected antibiotics in the past 2 weeks
- You have significant heart failure, a heart attack, or unstable chest pain within the past 6 months
- You have a serious long-term lung disease that requires you to use supplemental oxygen
- You have received an organ transplant and still take medicines to prevent rejection
- You have a history of cancer, except for certain treated skin cancers or a localized form of cervical pre-cancer
- You have active, latent, or inadequately treated tuberculosis (TB)
- You have a confirmed or suspected current COVID-19 infection
- You have had problems with drug or alcohol misuse within the past 6 months
- You have had major surgery in the past 3 months, or have major surgery planned during the study period
- A dermatologist has determined that you did not respond well enough to a previous treatment with a type of medicine called a JAK inhibitor, after taking it for at least 12 weeks
- You have taken certain medications that are not allowed by the study within specific timeframes before joining (confirm with trial site)
- You have taken part in another clinical trial within the past 4 weeks
- You have donated or lost about 500 mL (one unit) of blood in the past 4 weeks
- You have had cosmetic treatments or procedures that could affect how the study measures your vitiligo
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Merck Sharp & Dohme LLC
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percent Change From Baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24; Number of Participants Who Experienced an Adverse Event (AE); Number of Participants Who Discontinued Study Treatment Due to an AE
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.